A nonrandomized trial of vitamin D supplementation for Barrett's esophagus.

What Was Tested

This clinical trial looks at Vitamin D, K2, Magnesium and Zinc.

Vitamin D affects genes regulating proliferation, apoptosis, and differentiation and induces the tumor suppressor 15-hydroxyprostaglandin dehydrogenase (PGDH) in other cancers.

This nonrandomized interventional study assessed effects of vitamin D supplementation in Barrett's esophagus (BE).

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Esophageal biopsies from normal plus metaplastic BE epithelium and blood samples were obtained before and after vitamin D supplementation.

How the Study Was Run

The researchers set it up as a pilot study.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

Serum 25-hydroxyvitamin D was measured to characterize vitamin D status.

Esophageal gene expression was assessed using microarrays.

What Was Measured

This nonrandomized interventional study assessed effects of vitamin D supplementation in Barrett's esophagus (BE).

Topics PubMed links to this paper include Barrett Esophagus, Cholecalciferol, Gene Expression Regulation, Enzymologic, Hydroxyprostaglandin Dehydrogenases, Pilot Projects, Proton Pump Inhibitors and Vitamin D.

What This Means in Plain Language

The paper is a pilot study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.